Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.

Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ.

J Exp Med. 2001 Sep 17;194(6):823-32.

2.

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

Chambers CA, Kuhns MS, Egen JG, Allison JP.

Annu Rev Immunol. 2001;19:565-94. Review.

PMID:
11244047
3.

Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model.

Schreurs MW, Eggert AA, de Boer AJ, Vissers JL, van Hall T, Offringa R, Figdor CG, Adema GJ.

Cancer Res. 2000 Dec 15;60(24):6995-7001.

4.

Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.

Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD.

J Exp Med. 2000 Dec 4;192(11):1637-44.

5.

Design and evaluation of antigen-specific vaccination strategies against cancer.

Offringa R, van der Burg SH, Ossendorp F, Toes RE, Melief CJ.

Curr Opin Immunol. 2000 Oct;12(5):576-82. Review.

PMID:
11007362
6.

Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice.

Baxevanis CN, Voutsas IF, Tsitsilonis OE, Tsiatas ML, Gritzapis AD, Papamichail M.

Eur J Immunol. 2000 Jul;30(7):1957-66.

7.

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP.

Cancer Res. 2000 May 1;60(9):2444-8.

8.

Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo.

Bronte V, Apolloni E, Ronca R, Zamboni P, Overwijk WW, Surman DR, Restifo NP, Zanovello P.

Cancer Res. 2000 Jan 15;60(2):253-8.

9.

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, Burg MB.

Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15074-9.

10.

Coupling and uncoupling of tumor immunity and autoimmunity.

Bowne WB, Srinivasan R, Wolchok JD, Hawkins WG, Blachere NE, Dyall R, Lewis JJ, Houghton AN.

J Exp Med. 1999 Dec 6;190(11):1717-22.

11.

Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein.

Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R.

J Exp Med. 1999 Oct 4;190(7):1033-8.

12.

The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors.

Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A.

J Exp Med. 1999 Oct 4;190(7):1025-32.

15.

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP.

Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2982-7.

16.

The central role of CD4(+) T cells in the antitumor immune response.

Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H.

J Exp Med. 1998 Dec 21;188(12):2357-68.

17.

Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.

Okamoto T, Irie RF, Fujii S, Huang SK, Nizze AJ, Morton DL, Hoon DS.

J Invest Dermatol. 1998 Dec;111(6):1034-9.

PMID:
9856813
18.

Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.

Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA.

Cancer Res. 1998 Dec 1;58(23):5301-4.

19.

Fas and Fas ligand interactions suppress melanoma lung metastasis.

Owen-Schaub LB, van Golen KL, Hill LL, Price JE.

J Exp Med. 1998 Nov 2;188(9):1717-23.

20.

The role of CD4+ T cell responses in antitumor immunity.

Pardoll DM, Topalian SL.

Curr Opin Immunol. 1998 Oct;10(5):588-94. Review.

PMID:
9794842
Items per page

Supplemental Content

Write to the Help Desk